China Isotope & Radiation Corp
HKEX:1763
China Isotope & Radiation Corp
Cost of Revenue
China Isotope & Radiation Corp
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
China Isotope & Radiation Corp
HKEX:1763
|
Cost of Revenue
-¥3.2B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Cost of Revenue
-¥6.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
S
|
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
|
Cost of Revenue
-¥3.6B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-13%
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Cost of Revenue
-¥1.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Winner Medical Co Ltd
SZSE:300888
|
Cost of Revenue
-¥6.3B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Cost of Revenue
-¥1.1B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
See Also
What is China Isotope & Radiation Corp's Cost of Revenue?
Cost of Revenue
-3.2B
CNY
Based on the financial report for Dec 31, 2023, China Isotope & Radiation Corp's Cost of Revenue amounts to -3.2B CNY.
What is China Isotope & Radiation Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-27%
Over the last year, the Cost of Revenue growth was -20%. The average annual Cost of Revenue growth rates for China Isotope & Radiation Corp have been -24% over the past three years , -27% over the past five years .